GSK gets EC approval for new administration options of asthma treatment Nucala

This article was originally published here

Nucala, a pre-filled pen and a pre-filled safety syringe, is claimed to be the only monthly anti-IL5 biologic approved in Europe to treat patients with severe eosinophilic asthma

The post GSK gets EC approval for new administration options of asthma treatment Nucala appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply